Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Pfizer Inc.
< Previous
1
2
3
4
5
6
7
8
9
Next >
Pfizer Presents New Data at IDWeek 2023 Highlighting Advances in Prevention and Treatment of Certain Respiratory Illnesses and Other Infectious Diseases
October 05, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Declares Fourth-Quarter 2023 Dividend
October 04, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Broadens Portfolio of Respiratory Vaccines Recommended by CDC Advisory Committee with ABRYSVO™ for RSV
September 22, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
September 19, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
European Commission Approves Pfizer’s LITFULO™ for Adolescents and Adults With Severe Alopecia Areata
September 19, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of October 31 Conference Call with Analysts
September 18, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
September 12, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine
September 11, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
September 05, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union
August 30, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
Pfizer Invites Public to View and Listen to Two Webcasts of Pfizer Discussions at Healthcare Conferences
August 30, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
European Commission Approves Pfizer’s ABRYSVO™ to Help Protect Infants through Maternal Immunization and Older Adults from RSV
August 24, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Infants Through Active Immunization of Pregnant Individuals 32-36 Weeks of Gestational Age
August 21, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer’s ELREXFIO™ Receives U.S. FDA Accelerated Approval for Relapsed or Refractory Multiple Myeloma
August 14, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Reports Second-Quarter 2023 Results
August 01, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Announces Executive Leadership to Advance Oncology Research and Development Strategy
July 27, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Announces Post-Tornado Relief Plans for Rocky Mount Community and Manufacturing Facility
July 21, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Announces New England Journal of Medicine Publication on Group B Streptococcus (GBS) Maternal Vaccine Candidate
July 19, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
FDA Approves Pfizer’s NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency
June 28, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
OPK
PFE
FDA Accepts Pfizer’s Application for Hemophilia B Gene Therapy Fidanacogene Elaparvovec
June 27, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Provides Update on GLP-1-RA Clinical Development Program for Adults with Obesity and Type 2 Diabetes Mellitus
June 26, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
FDA Approves Pfizer’s LITFULO™ (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata
June 23, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Declares Third-Quarter 2023 Dividend
June 22, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer’s TALZENNA® in Combination with XTANDI® Receives U.S. FDA Approval
June 20, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of August 1 Conference Call with Analysts
June 20, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
June 06, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options
June 01, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults
May 31, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial
May 30, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Presents Scientific Advancements from its Leading Oncology Portfolio at ASCO 2023 Annual Meeting
May 25, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.